Enliven Therapeutics
Develops small-molecule therapies centered on ELVN-001 for chronic myeloid leukemia.
Something off on this page? Send us feedback.
Profile
Develops small-molecule precision medicines, centered on ELVN-001, a BCR-ABL inhibitor in global clinical development for chronic myeloid leukemia. With ELVN-002 no longer advanced internally, it has no approved products or revenue and depends on clinical execution, regulatory approval, and external financing.
Designs precision-medicine small molecules by combining validated biological targets, differentiated chemistry, and disciplined trial design. ELVN-001, a selective BCR-ABL kinase inhibitor for chronic myeloid leukemia, is the central program. It remains in a global Phase 1 trial while preparations continue for the ENABLE-2 pivotal study following FDA alignment on key design components.
ELVN-002, a CNS-penetrant HER2 inhibitor studied in solid tumors, is under strategic-alternatives review and is no longer being developed internally. The shift concentrates resources on ELVN-001 while additional small-molecule programs remain at the research stage.
Operates as one reportable segment, with no approved products or revenue. Clinical progress depends on patient enrollment, regulatory approval, capital, and outsourced research, trial, and manufacturing partners.
Company facts
Key statistics
Year to date +272% · Average volume (30d) 937.0K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 18, 2026 | Mizuho Securities | Target | $62 | $73 | |
| Aug 18, 2026 | William Blair | Initiate | Outperform | ||
| Aug 18, 2026 | Barclays | Initiate | Overweight | $78 | |
| Aug 6, 2026 | Stifel Nicolaus | Target | $80 | $82 | |
| Aug 6, 2026 | Guggenheim | Reiterate | Buy | $80 | $78 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026Q2 FY26 | −$0.39 | −$0.49 | −26.6% | — | — | — | +0.95% |
| May 7, 2026Q1 FY26 | −$0.44 | −$0.38 | +13.6% | — | — | — | +1.14% |
| Mar 3, 2026Q4 FY25 | −$0.42 | −$0.48 | −14.3% | $12.5K | — | — | +4.28% |
| Nov 12, 2025Q3 FY25 | −$0.43 | −$0.32 | +25.6% | $8.3K | — | — | −0.15% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | −$46.0K | −$14.0K | $0 | |
| Operating income | −$31.7M | −$28.6M | −$25.1M | −$34.3M | −$27.8M | −$37.2M | |
| Net income | −$28.5M | −$25.3M | −$20.1M | −$29.7M | −$23.6M | −$32.5M | |
| Diluted EPS | −$0.57 | −$0.49 | −$0.32 | −$0.45 | −$0.38 | −$0.49 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $895.2M · Total debt $1.5M · Total assets $910.2M · Shareholders' equity $895.1M
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 71.44M · Float 45.61M · 63.9% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 10.03M | 14.03% | 13F | Aug 13, 2026 |
| Orbimed Advisors LLC | 6.78M | 9.49% | 13F | Aug 14, 2026 |
| Polar Capital Holdings PLC | 6.43M | 9.00% | 13F | Aug 14, 2026 |
| BlackRock, Inc. | 4.36M | 6.10% | 13F | Aug 7, 2026 |
| Vestal Point Capital, LP | 4.00M | 5.60% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 17, 2026 | Helen Louise Collins | officer: CHIEF MEDICAL OFFICER | −5,000 | $58.59 |
| Aug 17, 2026 | Benjamin Hohl | officer: CHIEF FINANCIAL OFFICER | −6,018 | $58.58 |
| Aug 4, 2026 | Mika K. Derynck | director | −158,795 | $60.21 |
| Jul 17, 2026 | Helen Louise Collins | officer: CHIEF MEDICAL OFFICER | −5,000 | $52.67 |
| Jul 17, 2026 | Benjamin Hohl | officer: CHIEF FINANCIAL OFFICER | −6,018 | $52.64 |
Peers
- Novartis (ADR)
Dominant CML franchise around Scemblix
- Takeda (ADR)
Ponatinib sets the late-line CML benchmark
- Bristol-Myers Squibb
Approved dasatinib CML option
- Pfizer
Bosulif overlaps in approved CML TKI use
- Ascentage Pharma (ADR)
Olverembatinib is a global CML pipeline rival
- Merck
Owns TERN-701 after acquiring Terns
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Enliven Therapeutics | $57.69 | −0.27% | $4.13B | — | — | — | — |
| Novartis (ADR) | $153.81 | 0.00% | $292.35B | 23.2 | 16.4 | 5.3 | +0.9% |
| Takeda (ADR) | $18.49 | +2.53% | $57.37B | 51.0 | 53.7 | 2.0 | +5.8% |
| Bristol-Myers Squibb | $66.60 | +0.05% | $136.00B | 14.7 | 10.5 | 2.8 | +5.7% |
| Pfizer | $27.95 | −0.04% | $159.36B | 36.9 | 10.0 | 2.5 | +2.6% |
| Ascentage Pharma (ADR) | $17.98 | −0.08% | $1.70B | — | — | 18.0 | +37.8% |
| Merck | $148.19 | −0.08% | $366.18B | 118.7 | 17.2 | 5.5 | +5.1% |
| Median | 36.9 | 16.4 | 4.0 | +5.4% |